SAFETY DATA SHEET
generated by Regulation (EC) No. 1907/2006

Betamethasone / Gentamicin Formulation

Version: 2.4  Revision Date: 27.08.2021  SDS Number: 5345524-00006  Date of last issue: 09.04.2021

1. Product identifier
   Trade name: Betamethasone / Gentamicin Formulation

2. Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture: Veterinary product

3. Details of the supplier of the safety data sheet
   Company: MSD
   Kilsheelan
   Clonmel Tipperary, IE

   Telephone: 353-51-601000

   E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

4. Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2. Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Eye irritation, Category 2
   Reproductive toxicity, Category 1B
   Specific target organ toxicity - repeated exposure, Category 1
   Long-term (chronic) aquatic hazard, Category 1

   Hazard statements:
   H319: Causes serious eye irritation.
   H360D: May damage the unborn child.
   H372: Causes damage to organs through prolonged or repeated exposure.
   H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms: 
   Signal word: Danger
   Hazard statements: H319 Causes serious eye irritation.
   H360D May damage the unborn child.
   H372 Causes damage to organs through prolonged or repeated exposure.
   H410 Very toxic to aquatic life with long lasting effects.
Betamethasone / Gentamicin Formulation

Precautionary statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P273 Avoid release to the environment.
- P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
- P308 + P313 IF exposed or concerned: Get medical advice/ attention.
- P337 + P313 If eye irritation persists: Get medical advice/ attention.
- P391 Collect spillage.

Hazardous components which must be listed on the label:
- betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information:
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information:
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propan-2-ol</td>
<td>67-63-0</td>
<td>200-661-7</td>
<td>603-117-00-0</td>
<td>Flam. Liq. 2; H225 Eye Irrit. 2; H319 STOT SE 3; H336</td>
<td>=&gt; 10 - &lt; 20</td>
<td></td>
</tr>
<tr>
<td>Methyl p-Hydroxybenzoate</td>
<td>99-76-3</td>
<td>202-785-7</td>
<td></td>
<td>Aquatic Chronic 2; H411</td>
<td>=&gt; 1 - &lt; 2.5</td>
<td></td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>215-765-8</td>
<td></td>
<td>Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410</td>
<td>=&gt; 0.025 - &lt; 0.1</td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Betamethasone / Gentamicin Formulation

Version 2.4  Revision Date: 27.08.2021  SDS Number: 5345524-00006  Date of last issue: 09.04.2021

<table>
<thead>
<tr>
<th>Substance</th>
<th>M-Factor (Acute aquatic toxicity): 100</th>
<th>M-Factor (Chronic aquatic toxicity): 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>betamethasone</td>
<td>378-44-9</td>
<td>Acute Tox. 2; H330</td>
</tr>
<tr>
<td></td>
<td>206-825-4</td>
<td>Repr. 1B; H360D</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STOT RE 1; H372</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aquatic Chronic 1; H410</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt; = 0.025 - &lt; 0.1</td>
</tr>
</tbody>
</table>

M-Factor (Chronic aquatic toxicity): 1,000

Specific concentration limit
STOT RE 1; H372
>= 0.01 %
Repr. 1B; H360D
>= 0.01 %

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
**In case of eye contact**: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

**If swallowed**: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

**Risks**: Causes serious eye irritation. May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.

### 4.3 Indication of any immediate medical attention and special treatment needed

**Treatment**: Treat symptomatically and supportively.

---

**SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

**Suitable extinguishing media**: Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

**Unsuitable extinguishing media**: None known.

#### 5.2 Special hazards arising from the substance or mixture

**Specific hazards during firefighting**: Exposure to combustion products may be a hazard to health.

**Hazardous combustion products**: Carbon oxides

#### 5.3 Advice for firefighters

**Special protective equipment for firefighters**: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

**Specific extinguishing methods**: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation:
If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling:
Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
7.3 Specific end use(s)
Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>57-55-6</td>
<td>OELV - 8 hrs (TWA) (particles)</td>
<td>10 mg/m³</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OELV - 8 hrs (TWA) (total (vapour and particles))</td>
<td>150 ppm</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>470 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Propan-2-ol</td>
<td>67-63-0</td>
<td>OELV - 8 hrs (TWA)</td>
<td>200 ppm</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>OELV - 15 min (STEL)</td>
<td>400 ppm</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>TWA</td>
<td>0.1 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>betamethasone</td>
<td>378-44-9</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: Skin</td>
<td>Wipe limit</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10 µg/100 cm²</td>
<td></td>
</tr>
</tbody>
</table>
Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>168 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>50 mg/m³</td>
</tr>
<tr>
<td>Propan-2-ol</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>500 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>888 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>89 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>319 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>26 mg/kg bw/day</td>
</tr>
<tr>
<td>Methyl p-Hydroxybenzoate</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>58.76 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>9.8 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>14.49 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>4.2 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>4.16 mg/kg bw/day</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Fresh water</td>
<td>260 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>183 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>26 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>20000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>572 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>57.2 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>50 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Propan-2-ol</td>
<td>Fresh water</td>
<td>140.9 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>140.9 mg/l</td>
</tr>
<tr>
<td></td>
<td>Intermittent use/release</td>
<td>140.9 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>2251 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>552 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>552 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>
Betamethasone / Gentamicin Formulation

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.
If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material:
Chemical-resistant gloves

Remarks:
Consider double gloving.

Skin and body protection

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to I.S. EN 14387

Filter type:
Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state: liquid
Betamethasone / Gentamicin Formulation

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility: No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle characteristics</td>
<td>Particle size: Not applicable</td>
</tr>
</tbody>
</table>

### 9.2 Other information

**Explosives** : Not explosive

**Oxidizing properties** : The substance or mixture is not classified as oxidizing.

**Evaporation rate** : No data available

**Molecular weight** : No data available
SECTION 10: Stability and reactivity

10.1 Reactivity
   Not classified as a reactivity hazard.

10.2 Chemical stability
   Stable under normal conditions.

10.3 Possibility of hazardous reactions
   Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
   Conditions to avoid: None known.

10.5 Incompatible materials
   Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
   No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
   Information on likely routes of exposure:
   - Inhalation
   - Skin contact
   - Ingestion
   - Eye contact

   Acute toxicity
   Not classified based on available information.

   Components:

   Propan-2-ol:
   - Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
   - Acute inhalation toxicity: LC50 (Rat): > 25 mg/l
     Exposure time: 6 h
     Test atmosphere: vapour

   Methyl p-Hydroxybenzoate:
   - Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
     Method: OECD Test Guideline 401

   Gentamicin:
   - Acute oral toxicity: LD50 (Rat): 8,000 - 10,000 mg/kg
Betamethasone / Gentamicin Formulation

LD50 (Mouse): 10,000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 0.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration):
LD50 (Rat): 67 - 96 mg/kg
Application Route: Intravenous
LD50 (Rat): 371 - 384 mg/kg
Application Route: Intramuscular
LDLo (Monkey): 30 mg/kg
Application Route: Intravenous

betamethasone:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity: LC50 (Rat): 0.4 mg/l
Exposure time: 4 h

Skin corrosion/irritation
Not classified based on available information.

Components:

Propan-2-ol:
Species: Rabbit
Result: No skin irritation

Methyl p-Hydroxybenzoate:
Species: Rabbit
Result: No skin irritation

Gentamicin:
Species: Rabbit
Result: Mild skin irritation

betamethasone:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.
Components:

Propan-2-ol:
Species: Rabbit
Result: Irritation to eyes, reversing within 21 days

Methyl p-Hydroxybenzoate:
Species: Rabbit
Result: No eye irritation

Gentamicin:
Species: Rabbit
Result: Mild eye irritation

betamethasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Propan-2-ol:
Test Type: Buehler Test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative

Methyl p-Hydroxybenzoate:
Test Type: Maurer optimisation test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative

Gentamicin:
Remarks: No data available

betamethasone:
Exposure routes: Dermal
Species: Guinea pig
Result: Weak sensitizer
Germ cell mutagenicity
Not classified based on available information.

Components:

Propan-2-ol:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Methyl p-Hydroxybenzoate:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: positive

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 478
Result: negative

Gentamicin:
Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intravenous injection
Result: negative

Betamethasone:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative
Betamethasone / Gentamicin Formulation

Test Type: Chromosome aberration test in vitro
Result: positive

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Oral
Result: equivocal

Germ cell mutagenicity - Assessment
Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

Propan-2-ol:
Species: Rat
Application Route: Inhalation (vapour)
Exposure time: 104 weeks
Method: OECD Test Guideline 451
Result: negative

Gentamicin:
Carcinogenicity - Assessment: No data available

Reproductive toxicity
May damage the unborn child.

Components:

Propan-2-ol:
Effects on fertility:
Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development:
Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

Methyl p-Hydroxybenzoate:
Effects on foetal development:
Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: negative

Gentamicin:
Effects on fertility: Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Fertility: NOAEL: 20 mg/kg body weight  
Result: No significant adverse effects were reported

Effects on foetal development: Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 75 mg/kg body weight  
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Intraperitoneal  
Developmental Toxicity: NOAEL: 3.6 mg/kg body weight  
Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 50 mg/kg body weight  
Result: foetal mortality, No malformations were observed.

Reproductive toxicity - Assessment: Positive evidence of adverse effects on development from human epidemiological studies.

**betamethasone:**

Effects on foetal development: Species: Rabbit  
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 0.05 mg/kg body weight  
Result: Fetotoxicity, Malformations were observed.

Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: LOAEL: 0.42 mg/kg body weight  
Result: Malformations were observed.

Species: Mouse  
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 1 mg/kg body weight  
Result: Malformations were observed.

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.
Betamethasone / Gentamicin Formulation

Components:

Propan-2-ol:
Assessment : May cause drowsiness or dizziness.

STOT - repeated exposure
Causes damage to organs through prolonged or repeated exposure.

Components:

Gentamicin:
Target Organs : Kidney, inner ear
Assessment : Causes damage to organs through prolonged or repeated exposure.

Betamethasone:
Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Propan-2-ol:
Species : Rat
NOAEL : 12.5 mg/l
Application Route : inhalation (vapour)
Exposure time : 104 Weeks

Methyl p-Hydroxybenzoate:
Species : Rat
NOAEL : 250 mg/kg
LOAEL : 1,000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days
Method : OECD Test Guideline 407

Gentamicin:
Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney
Symptoms : Vomiting, Salivation

Species : Monkey
LOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Weeks
**Betamethasone / Gentamicin Formulation**

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>Kidney, inner ear</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species</strong></td>
<td>Monkey</td>
</tr>
<tr>
<td><strong>LOAEL</strong></td>
<td>6 mg/kg</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Intramuscular</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>3 Weeks</td>
</tr>
<tr>
<td><strong>Target Organs</strong></td>
<td>Blood, Kidney, inner ear, Liver</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>Blood, Kidney, Liver</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species</strong></td>
<td>Rat</td>
</tr>
<tr>
<td><strong>NOAEL</strong></td>
<td>5 mg/kg</td>
</tr>
<tr>
<td><strong>LOAEL</strong></td>
<td>10 mg/kg</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Intramuscular</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>52 Weeks</td>
</tr>
<tr>
<td><strong>Target Organs</strong></td>
<td>Kidney, Blood</td>
</tr>
</tbody>
</table>

**Betamethasone:**

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>Pituitary gland, Immune system, muscle</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species</strong></td>
<td>Rabbit</td>
</tr>
<tr>
<td><strong>LOAEL</strong></td>
<td>0.05 %</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Skin contact</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>10 - 30 d</td>
</tr>
<tr>
<td><strong>Target Organs</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>thymus gland</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species</strong></td>
<td>Rat</td>
</tr>
<tr>
<td><strong>LOAEL</strong></td>
<td>0.05 %</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Skin contact</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>8 Weeks</td>
</tr>
<tr>
<td><strong>Target Organs</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>thymus gland</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species</strong></td>
<td>Mouse</td>
</tr>
<tr>
<td><strong>LOAEL</strong></td>
<td>0.1 %</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Skin contact</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>8 Weeks</td>
</tr>
<tr>
<td><strong>Target Organs</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>Blood, thymus gland, Adrenal gland</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Species</strong></td>
<td>Dog</td>
</tr>
<tr>
<td><strong>LOAEL</strong></td>
<td>0.05 mg/kg</td>
</tr>
<tr>
<td><strong>Application Route</strong></td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Exposure time</strong></td>
<td>28 d</td>
</tr>
<tr>
<td><strong>Target Organs</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Aspiration toxicity**

Not classified based on available information.
11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:
Gentamicin:
Ingestion : Target Organs: Kidney
Target Organs: inner ear
Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

betamethasone:
Inhalation : Target Organs: Adrenal gland
Skin contact : Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:
Propan-2-ol:
Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 9,640 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 24 h

Toxicity to microorganisms : EC50 (Pseudomonas putida): > 1,050 mg/l
Exposure time: 16 h

Methyl p-Hydroxybenzoate:
Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 59.5 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 11.2 mg/l
Exposure time: 48 h
Method: ISO 6341

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): 91 mg/l
Exposure time: 72 h
Betamethasone / Gentamicin Formulation

Method: ISO 8692

EC10 (Pseudokirchneriella subcapitata (green algae)): 31 mg/l
Exposure time: 72 h
Method: ISO 8692

Toxicity to fish (Chronic toxicity) :

NOEC: 0.024 mg/l
Exposure time: 70 d
Species: Danio rerio (zebra fish)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) :

NOEC: 0.2 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Gentamicin:

Toxicity to daphnia and other aquatic invertebrates :

EC50 (Daphnia magna (Water flea)): 86 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants :

EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) :

100

Toxicity to microorganisms :

EC50 : 288.7 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

M-Factor (Chronic aquatic toxicity) :

1

betamethasone:

Toxicity to daphnia and other :

EC50 (Americamysis): > 50 mg/l
aquatic invertebrates: Exposure time: 96 h

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
- Exposure time: 72 h
- Method: OECD Test Guideline 201
- Remarks: No toxicity at the limit of solubility
- NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l
- Exposure time: 72 h
- Method: OECD Test Guideline 201
- Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity):
- NOEC: 0.052 mg/l
- Exposure time: 32 d
- Species: Pimephales promelas (fathead minnow)
- Method: OECD Test Guideline 210
- NOEC: 0.07 µg/l
- Exposure time: 219 d
- Species: Oryzias latipes (Japanese medaka)
- Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC: 8 mg/l
- Exposure time: 21 d
- Species: Daphnia magna (Water flea)
- Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity): 1,000

12.2 Persistence and degradability

Components:

Propan-2-ol:
- Biodegradability: Result: rapidly degradable
- BOD/COD: BOD: 1.19 (BOD5)
  COD: 2.23
  BOD/COD: 53 %

Methyl p-Hydroxybenzoate:
- Biodegradability: Result: Readily biodegradable.
  Biodegradation: 89 %
  Exposure time: 28 d
  Method: OECD Test Guideline 301B

Gentamicin:
- Biodegradability: Result: rapidly degradable
  Biodegradation: 100 %
  Exposure time: 28 d
12.3 Bioaccumulative potential

**Components:**

**Propan-2-ol:**
Partition coefficient: n-octanol/water : log Pow: 0.05

**Methyl p-Hydroxybenzoate:**
Partition coefficient: n-octanol/water : log Pow: 1.98

**Gentamicin:**
Partition coefficient: n-octanol/water : log Pow: < -2

**betamethasone:**
Partition coefficient: n-octanol/water : log Pow: 2.11

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment

**Product:**
Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product** : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

<table>
<thead>
<tr>
<th>Code</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>UN 3082</td>
</tr>
<tr>
<td>ADR</td>
<td>UN 3082</td>
</tr>
<tr>
<td>RID</td>
<td>UN 3082</td>
</tr>
<tr>
<td>IMDG</td>
<td>UN 3082</td>
</tr>
<tr>
<td>IATA</td>
<td>UN 3082</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)</td>
</tr>
<tr>
<td>ADR</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)</td>
</tr>
<tr>
<td>RID</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)</td>
</tr>
<tr>
<td>IMDG</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (betamethasone)</td>
</tr>
<tr>
<td>IATA</td>
<td>Environmentally hazardous substance, liquid, n.o.s. (betamethasone)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th>Code</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>9</td>
</tr>
<tr>
<td>ADR</td>
<td>9</td>
</tr>
<tr>
<td>RID</td>
<td>9</td>
</tr>
<tr>
<td>IMDG</td>
<td>9</td>
</tr>
<tr>
<td>IATA</td>
<td>9</td>
</tr>
</tbody>
</table>

14.4 Packing group

<table>
<thead>
<tr>
<th>Code</th>
<th>Group</th>
<th>Classification Code</th>
<th>Hazard Identification Number</th>
<th>Labels</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>III</td>
<td>M6</td>
<td>90</td>
<td>9</td>
</tr>
<tr>
<td>ADR</td>
<td>III</td>
<td>M6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Betamethasone / Gentamicin Formulation

<table>
<thead>
<tr>
<th>Hazard Identification Number</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labels</td>
<td>9</td>
</tr>
<tr>
<td>Tunnel restriction code</td>
<td>(-)</td>
</tr>
</tbody>
</table>

**RID**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9

**IMDG**
- Packing group: III
- Labels: 9
- EmS Code: F-A, S-F

**IATA (Cargo)**
- Packing instruction (cargo aircraft): 964
- Packing instruction (LQ): Y964
- Packing group: III
- Labels: Miscellaneous

**IATA (Passenger)**
- Packing instruction (passenger aircraft): 964
- Packing instruction (LQ): Y964
- Packing group: III
- Labels: Miscellaneous

### 14.5 Environmental hazards

**ADN**
- Environmentally hazardous: yes

**ADR**
- Environmentally hazardous: yes

**RID**
- Environmentally hazardous: yes

**IMDG**
- Marine pollutant: yes

**IATA (Passenger)**
- Environmentally hazardous: yes

**IATA (Cargo)**
- Environmentally hazardous: yes

### 14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Maritime transport in bulk according to IMO instruments
- Remarks: Not applicable for product as supplied.
SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII):
- Conditions of restriction for the following entries should be considered: Number on list 3
- Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59):
- Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer:
- Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast):
- Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals:
- Not applicable

REACH - List of substances subject to authorisation (Annex XIV):
- Not applicable


<table>
<thead>
<tr>
<th>Number on list</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
- Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
- Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information:
- Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H225: Highly flammable liquid and vapour.
H319: Causes serious eye irritation.
H330: Fatal if inhaled.
H336: May cause drowsiness or dizziness.
H360D: May damage the unborn child.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Betamethasone / Gentamicin Formulation

Version 2.4 Revised Date: 27.08.2021
SDS Number: 5345524-00006
Date of last issue: 09.04.2021
Date of first issue: 09.12.2019

H372 : Causes damage to organs through prolonged or repeated exposure.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.
H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Flam. Liq. : Flammable liquids
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure
STOT SE : Specific target organ toxicity - single exposure
IE OEL : Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min (STEL) : Occupational exposure limit value (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50 % of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - United States Code Title 15, Section 2604; TRIPS - Agreement on Trade-Related Aspects of Intellectual Property Rights; TWA - Time Weighted Average; USCG - United States Coast Guard; VEG - Value of Effective Generation; VECI - Value of Effective Consumption; Welding Procedure Specification; Working Time Regulation.
Betamethasone / Gentamicin Formulation

Further information
Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:

<table>
<thead>
<tr>
<th>Classification</th>
<th>Classification procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye Irrit. 2</td>
<td>H319</td>
</tr>
<tr>
<td>Repr. 1B</td>
<td>H360D</td>
</tr>
<tr>
<td>STOT RE 1</td>
<td>H372</td>
</tr>
<tr>
<td>Aquatic Chronic 1</td>
<td>H410</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN